

**Supplementary Figure 1: Limit of Detection experiment for the 8 colour FCM MRD assay. The plot on upper left represents the leukemic sample. The upper right plot shows dilution at 1%, the lower left and right plots show dilution at 0.1 and 0.01%.**

|  |  |  |  |
| --- | --- | --- | --- |
| **PI MRD Positive (n=108\*)** | **Did Not Relapse (68)** | **Relapsed (40)** | **p value** |
| Favorable Cytogenetics | 22 | 11 | p=0.88 |
| Intermediate Cytogenetics | 36 | 19 |
| Poor Cytogenetics | 10 | 10 |
| *FLT3*-ITD Positive | 14 | 8 |
| *FLT3*-ITD Negative | 54 | 32 |
| *NPM1* Positive | 13 | 12 |
| *NPM1* Negative | 55 | 28 |
| *CEBPA* Positive | 5 | 2 |
| *CEBPA* Negative | 62 | 35 |
| **PI MRD Negative (n=191)** | **Did Not Relapse (151)** | **Relapsed (41)** |  |
| Favorable Cytogenetics | 55 | 14 | p=0.47 |
| Intermediate Cytogenetics | 86 | 20 |
| Poor Cytogenetics | 9 | 7 |
| *FLT3*-ITD Positive | 35 | 10 |
| *FLT3*-ITD Negative | 114 | 31 |
| *NPM1* Positive | 47 | 18 |
| *NPM1* Negative | 102 | 23 |
| *CEBPA* Positive | 14 | 3 |
| *CEBPA* Negative | 128 | 33 |

**Supplementary Table 1: Differences in characteristics of patients who were post induction MRD positive and relapsed/ post induction MRD positive and did not relapse as well as patients who were post induction MRD negative and relapsed/ post induction MRD negative and did not relapse. \*One patient was excluded from this analysis as he died during the consolidation phase of therapy**